ArticleFrontiers in cellular and infection microbiology2023
Gut microbiome and mycobiome in inflammatory bowel disease patients with
Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gut Mycobiome in Inflammatory Bowel Disease: A Systematic Review of Case-Control Studies.Inflammatory bowel diseases · 2025Pooled it
- Transferable genetic toolsets for nonmodel gut Clostridia enable in vivo reversible control of metabolite production.Nature biotechnology · 2026Article
- Article
- Biomarkers for Early Severity Prediction inMedicina (Kaunas, Lithuania) · 2026Review
- Unveiling the diagnostic and pro-inflammatory role of crohn's disease: insights from 16 S-guided discovery and species-specific validation.BMC gastroenterology · 2025Article
- Microbiome Markers in Gastrointestinal Disorders: Inflammatory Bowel Disease, Colorectal Cancer, and Celiac Disease.International journal of molecular sciences · 2025Review
- The gastrointestinal mycobiome in inflammation and cancer: unraveling fungal dysbiosis, pathogenesis, and therapeutic potential.Medical oncology (Northwood, London, England) · 2025Review
- The Gut Mycobiome for Precision Medicine.Journal of fungi (Basel, Switzerland) · 2025Review
- Insights into the Interaction BetweenJournal of personalized medicine · 2025Review
- Sex-Induced Changes in Microbial Eukaryotes and Prokaryotes in Gastrointestinal Tract of Simmental Cattle.Biology · 2024Article
- The Role of Gut Microbiome in the Pathogenesis and the Treatment of Inflammatory Bowel Diseases.Cureus · 2024Review
- Gut Microbiota-Gut Metabolites andMetabolites · 2024Review
- Causal relationship between gut microbiota and hidradenitis suppurativa: a two-sample Mendelian randomization study.Frontiers in microbiology · 2024Article
- An Update on the Role and Potential Molecules in Relation toDiabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- The gut-lung axis: the impact of the gut mycobiome on pulmonary diseases and infections.Oxford open immunology · 2024Review
- Clostridioides difficile Infection in Pediatric Inflammatory Bowel Disease.Current gastroenterology reports · 2023Review
- From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: We collected fecal samples from patients with active IBD and concomitant CDI (IBD-CDI group, n=25), patients with active IBD and no CDI (IBD-only group, n=51), and healthy subjects (HC, n=40). Patients' characteristics including demographic data, disease severity, and medication history were collected. Metagenomic sequencing, taxonomic and functional analysis were carried out in the samples. Results: We found that the bacterial alpha diversity of the IBD-CDI group was decreased. The bacterial and fungal beta diversity variations between IBD patients and HC were significant, regardless of CDI status. But the IBD-CDI group did not significantly cluster separately from the IBD-only group. Several bacterial taxa, including Conclusion: IBD patients with CDI had pronounced microbial dysbiosis. Gut micro-ecological changes in IBD patients with CDI might provide insight into the pathological process and potential strategies for diagnosis and treatment in this subset of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.